Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab

about

Double trouble: Complement-mediated thrombotic microangiopathy in patients with hemoglobinopathies after stem cell transplantation.Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease

P2860

Q52774563-EEC2A100-E793-408F-A429-35746FBAFC71 Q58793738-11C0A114-BAB4-43C6-9046-35E1A665B8B2

P2860

Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab

Item

http://www.wikidata.org/entity/Q42738030

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Atypical haemolytic uraemic sy ...... sfully treated with eculizumab

@en

Atypical haemolytic uraemic sy ...... sfully treated with eculizumab

@nl

type

Item

label

Atypical haemolytic uraemic sy ...... sfully treated with eculizumab

@en

Atypical haemolytic uraemic sy ...... sfully treated with eculizumab

@nl

prefLabel

Atypical haemolytic uraemic sy ...... sfully treated with eculizumab

@en

Atypical haemolytic uraemic sy ...... sfully treated with eculizumab

@nl

P1476

Atypical haemolytic uraemic sy ...... sfully treated with eculizumab

@en

P2093

David Ingala

http://www.w3.org/2001/XMLSchema#string

Karen Ann Kalinyak

http://www.w3.org/2001/XMLSchema#string

Ralph Gruppo

http://www.w3.org/2001/XMLSchema#string

Shanmuganathan Chandrakasan

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome

The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.

Thrombotic thrombocytopenic purpura in a patient with sickle cell crisis.

Life-threatening thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease.

Alternative complement pathway assessment in patients with atypical HUS.

Thrombotic microangiopathy in sickle cell disease crisis.

Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.

How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome.

A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome.

Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients

P304

744-747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13884

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

175

http://www.w3.org/2001/XMLSchema#string

P50

Theodosia A. Kalfa

Satheesh Chonat

P577

2015-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287807901

http://www.w3.org/2001/XMLSchema#string

P698

27870017

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

5545798

http://www.w3.org/2001/XMLSchema#string

Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab

about

P2860

P2860

Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932